HORIZON

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

Study type: Interventional

Site and lead:

• Oxford Road Campus: Dr Stephen Hughes

Patient group: SARS-CoV-2 seronegative adults

Intervention: Ad26.COV2.S Vaccine